The combination of SH003 and DTX induces cytotoxic cell infiltration in anti-PD1 resistant lung cancer

The combination of SH003 and DTX induces cytotoxic cell infiltration in anti-PD1 resistant lung cancer

Abstract The development of therapeutic strategies to overcome resistance to anti-PD1 therapies in lung cancer remains a significant challenge. Based on our recent findings of SH003’s immunomodulatory capabilities, this study investigates the combined effects of SH003 and docetaxel (DTX) as a potent...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu-Jeong Choi, Sang-Eun Lee, Daeun Kim, Hae-In Lim, Da Kyung Choi, Bong Kyu Park, Chan-Yong Jeon, Seong-Gyu Ko
Format: Article
Language:English
Published: Springer 2025-05-01
Series:Cancer Immunology, Immunotherapy
Subjects:
SH003
Docetaxel
Combination treatment
Anti-PD1 resistance
Lung cancer
EGFR/JAK/STAT3 pathway
Online Access:https://doi.org/10.1007/s00262-025-04064-6
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The development of therapeutic strategies to overcome resistance to anti-PD1 therapies in lung cancer remains a significant challenge. Based on our recent findings of SH003’s immunomodulatory capabilities, this study investigates the combined effects of SH003 and docetaxel (DTX) as a potential second-line therapy in an anti-PD1-resistant lung cancer model. Our results demonstrate that SH003 and DTX effectively inhibit tumor growth by inducing apoptosis in an anti-PD1-resistant lung cancer LLC1 model, while enhancing the infiltration of cytotoxic CD8 + T cells and NK cells into the tumor microenvironment (TME), thereby boosting anti-tumor immunity. SH003 also exhibited immunomodulatory effects in an immunosuppressed mouse model, further emphasizing its potential in enhancing immune responses. Notably, the combination treatment significantly inhibits tumor growth by targeting the EGFR/JAK/STAT3 signaling pathway, contributing to the reduction of PD-L1 expression associated with immune evasion. These findings elucidate the dual mechanism of action of the SH003-DTX combination in overcoming resistance through both direct anticancer effects and immune system modulation. Overall, these findings demonstrate that the SH003-DTX combination presents a promising approach for anti-PD1-refractory lung cancer patients, potentially offering new treatment possibilities where current options are limited.
ISSN:1432-0851

Similar Items